Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
Top Page
BioNTech SE
(NASDAQ:BNTX)
58Neutral
Positive Factors
Clinical Trial Success
The success of the HARMONi-6 trial is seen as a positive indicator for BioNTech in global markets.
Financial Performance
BioNTech recorded net earnings per diluted share of €1.08 per share—greater than the previous forecast for net earnings of €0.04 per share.
Pipeline and Development
BioNTech remains an intriguing opportunity based on its substantial war chest, burgeoning pipeline beyond vaccines, and plethora of upcoming data releases.
Negative Factors
Data Maturity Concerns
The key concern is whether preliminary signals, especially overall survival, can hold as the data remains highly immature.
Projected Financial Loss
There is a projection of a full-year 2025 net loss per diluted share of €4.87, which is a greater loss than the prior estimate of €4.64 per share.
BioNTech SE (BNTX) vs. S&P 500 (SPY)
Market Cap
$24.48B
Dividend YieldN/A
Average Volume (3M)1.07M
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue Growth-27.64%
EPS Growth-172.62%
CountryUS
Employees6,772
SectorHealthcare
Sector Strength69
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.02
Shares Outstanding239,970,810
10 Day Avg. Volume1,290,191
30 Day Avg. Volume1,066,907
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.62
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$139.56Price Target Upside36.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
BioNTech SE Business Overview & Revenue Model
Company DescriptionBioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
How the Company Makes MoneyBioNTech SE generates revenue through the development and commercialization of its mRNA-based therapies and vaccines. A significant portion of its income is derived from its collaboration with Pfizer, particularly from the sales of the COVID-19 vaccine, which has been distributed globally. The company also engages in strategic partnerships and licensing agreements with other pharmaceutical firms to enhance its development pipeline and expand its market reach. Additionally, BioNTech earns revenue through research grants and milestone payments associated with the progress of its clinical trials and product developments.
BioNTech SE Financial Statement Overview
Summary
BioNTech SE's financial performance shows mixed results. While the balance sheet is strong with a low debt-to-equity ratio and high equity ratio, income and cash flow metrics have been volatile. Recent revenue and profit margin declines, combined with fluctuating cash flows, indicate potential areas for improvement.Income Statement
BioNTech SE has experienced significant volatility in its revenue and profitability margins. The gross profit margin has generally been strong, averaging 80% during peak years, but has recently decreased. Net profit margin has also shown volatility, with recent negative figures after previous years of profitability. The revenue growth rate has been inconsistent, with a notable decline in recent years following a peak period.65
Positive
Balance Sheet
The balance sheet of BioNTech SE is robust, with a strong equity ratio averaging around 85% over the years, indicating solid financial stability. The company has maintained a low debt-to-equity ratio, reflecting prudent financial management. However, the return on equity has been volatile due to fluctuating net income, indicating potential concerns in sustained profitability.75
Positive
Cash Flow
BioNTech SE's cash flow statement reveals fluctuating free cash flow, with recent negative figures following a period of strong positive cash flow. The operating cash flow to net income ratio has also varied significantly, pointing to inconsistencies in cash generation relative to reported profits. This variability poses a risk to cash flow stability.60
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 2.75B | 3.82B | 17.31B | 18.98B | 482.32M | Gross Profit |
| 2.21B | 3.22B | 12.78B | 15.12B | -222.04M | EBIT |
| -1.31B | 690.40M | 12.64B | 15.28B | -82.42M | EBITDA |
| -367.10M | 1.09B | 12.86B | 15.73B | -97.89M | Net Income Common Stockholders |
| -665.30M | 930.30M | 9.43B | 10.29B | 15.20M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 16.78B | 16.55B | 14.06B | 2.07B | 1.35B | Total Assets |
| 22.53B | 23.01B | 23.28B | 15.83B | 2.32B | Total Debt |
| 254.20M | 219.10M | 212.20M | 301.50M | 240.19M | Net Debt |
| -9.51B | -11.44B | -13.66B | -1.39B | -970.02M | Total Liabilities |
| 3.12B | 2.76B | 3.22B | 3.94B | 946.77M | Stockholders Equity |
| 19.41B | 20.25B | 20.06B | 11.89B | 1.37B |
| Cash Flow | Free Cash Flow | |||
| -244.60M | 4.67B | 13.21B | 735.70M | -98.92M | Operating Cash Flow |
| 207.70M | 5.37B | 13.58B | 889.70M | -13.47M | Investing Cash Flow |
| -2.08B | -6.95B | -35.30M | -566.10M | -144.85M | Financing Cash Flow |
| -45.90M | -778.60M | -1.42B | 94.20M | 894.73M |
BioNTech SE Technical Analysis
Negative
102.02
Price Trends
103.44
Negative
110.35
Negative
105.95
Negative
Market Momentum
2.31
Negative
50.69
Neutral
71.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTX, the sentiment is Negative. The current price of 102.02 is above the 20-day moving average (MA) of 97.46, below the 50-day MA of 103.44, and below the 200-day MA of 105.95, indicating a neutral trend. The MACD of 2.31 indicates Negative momentum. The RSI at 50.69 is Neutral, neither overbought nor oversold. The STOCH value of 71.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNTX.
BioNTech SE Risk Analysis
BioNTech SE disclosed 1 risk factors in its most recent earnings report. BioNTech SE reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioNTech SE Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $129.99B | 16.17 | 9.05% | 7.37% | 8.77% | 272.80% | |
58 Neutral | $24.48B | ― | -3.38% | ― | -27.64% | -172.62% | |
54 Neutral | $347.17M | ― | -46.85% | ― | -100.00% | 72.73% | |
51 Neutral | $5.32B | 3.32 | -40.25% | 2.90% | 17.93% | 2.14% | |
46 Neutral | $1.07B | ― | 30.06% | ― | -30.65% | 77.62% | |
46 Neutral | $10.50B | ― | -28.77% | ― | -52.75% | 25.00% | |
33 Underperform | $68.58M | ― | -115.42% | ― | -73.83% | 34.81% |
* Healthcare Sector Average
Performance Comparison
BNTX
BioNTech SE
102.02
14.07
16.00%
INO
Inovio Pharmaceuticals
1.87
-9.63
-83.74%
NVAX
Novavax
6.67
2.38
55.48%
PFE
Pfizer
22.92
-1.21
-5.01%
BNTC
Benitec Biopharma
13.59
6.16
82.91%
MRNA
Moderna
27.22
-84.40
-75.61%
BioNTech SE Earnings Call Summary
Earnings Call Date: Mar 10, 2025 | % Change Since: -6.21% | Next Earnings Date: May 5, 2025
Earnings Call Sentiment Neutral
The earnings call presents a mixed outlook for BioNTech. While there are significant advancements in their oncology pipeline and strategic acquisitions like Biotheus, challenges remain with declining COVID-19 vaccine revenues and ongoing legal costs. Financial losses for 2024 also highlight some operational difficulties. The sentiment is balanced between optimism for future growth and caution due to current financial and operational challenges.Highlights
Oncology Pipeline Expansion
BioNTech has significantly increased the number of Phase 2 and 3 trials, especially for their mRNA cancer immunotherapies and BNT327. This expansion aligns with their long-term strategy to focus on high-priority programs like BNT327 and personalized mRNA cancer immunotherapies.
BNT327 Clinical Development
BioNTech initiated multiple trials for BNT327, a PD-L1/VEGF bispecific antibody, in small cell lung cancer, non-small cell lung cancer, and triple-negative breast cancer. The company also acquired Biotheus to enhance global capabilities for BNT327 development.
mRNA Cancer Immunotherapy Progress
Significant progress was made with the FixVac and iNeST platforms. FixVac candidate BNT111 met the primary endpoint in a Phase 2 trial for melanoma. The iNeST platform showed promising immune responses in Phase 1 trials, leading to ongoing Phase 2 trials in colorectal cancer, pancreatic cancer, and bladder cancer.
Financial Performance and Guidance
BioNTech reported EUR2.8 billion in revenue for 2024, meeting the midpoint of their guidance. They maintain a strong cash position of EUR17.4 billion. The 2025 revenue guidance is set between EUR1.7 billion and EUR2.2 billion.
Biotheus Acquisition
BioNTech completed the acquisition of Biotheus to secure global control over BNT327 and expand their immunotherapy capabilities, especially in China.
Lowlights
COVID-19 Vaccine Revenue Decline
Revenue decreased from EUR3.8 billion in 2023 to EUR2.8 billion in 2024, primarily due to lower COVID-19 vaccine demand and write-downs by Pfizer.
Legal Settlement Costs
BioNTech incurred significant costs related to settlements with NIH and the University of Pennsylvania, totaling approximately $1.6 billion. This impacted their 2024 financial results.
iNeST Platform Challenges
The Phase 2 trial for the iNeST platform in metastatic melanoma did not meet its primary endpoint for progression-free survival, although a trend favoring the combination arm was observed.
Financial Losses
BioNTech reported a net loss of EUR665 million for 2024, compared to a net profit of EUR930 million in 2023, primarily due to lower revenues and increased expenses.
Company Guidance
During the BioNTech fourth quarter and full-year 2024 earnings call, the company provided guidance on several key metrics and strategic priorities for 2025. BioNTech expects total revenues to range between EUR 1.7 billion and EUR 2.2 billion, assuming stable vaccination rates and market share for COVID-19 vaccines, while anticipating some inventory write-downs and charges. Research and development (R&D) expenses are projected to be between EUR 2.6 billion and EUR 2.8 billion, driven by increased investment in late-stage programs such as BNT327 and mRNA cancer immunotherapies. Selling, general, and administrative (SG&A) expenses are expected to rise to between EUR 650 million and EUR 750 million, reflecting the company's commercial expansion in oncology. Additionally, capital expenditures are expected to reach EUR 250 million to EUR 350 million. The call emphasized the strategic focus on two pan-tumor programs, BNT327 and mRNA cancer immunotherapies, with several clinical and regulatory milestones anticipated throughout the year, including data updates across various oncology trials and potential regulatory filings.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.